

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/665,883	09/19/2003	Chong-Sheng Yuan	466992001100 6779 EXAMINER	
25225 7	590 02/02/2006			
MORRISON & FOERSTER LLP			PATTERSON, CHARLES L JR	
SUITE 100	LUFF DRIVE		ART UNIT	PAPER NUMBER
SAN DIEGO,	CA 92130-2040		1652	
			DATE MAILED: 02/02/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Comment	10/665,883	YUAN, CHONG-SHENG
Office Action Summary	Examiner	Art Unit
	Charles L. Patterson, Jr.	1652
The MAILING DATE of this communication ap Period for Reply	opears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING [- Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO .136(a). In no event, however, may a reply be tid d will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDON.	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on 30 graphs 2a) ☐ This action is FINAL . 2b) ☐ This action is FINAL . 2b) ☐ This action is in condition for allows closed in accordance with the practice under	is action is non-final. ance except for formal matters, pr	rosecution as to the merits is
Disposition of Claims		
 4) ☐ Claim(s) 1-72 is/are pending in the applicatio 4a) Of the above claim(s) 1-30 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 31-72 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/ 	vn from consideration.	
Application Papers		
9) ☐ The specification is objected to by the Examin 10) ☐ The drawing(s) filed on 19 September 2003 is Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) ☐ The oath or declaration is objected to by the Examination is objected.	s/are: a) accepted or b) object of a drawing(s) be held in abeyance. Section is required if the drawing(s) is objection.	ee 37 CFR 1.85(a). Djected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. Its have been received in Applicatority documents have been received (PCT Rule 17.2(a)).	tion No red in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal C 6) Other:	

Application/Control Number: 10/665,883

Art Unit: 1652

Applicants' election with traverse of Group IV, claims 50-72 in the reply filed on 12/27/05 is acknowledged. The traversal is on the ground(s) that Groups III and IV are in the same class and subclass and there would be no undue search burden. After further consideration the examiner will examine Groups III and IV, claims 31-72. It is noted that applicant characterize Group IV as claims 50-77, but apparently it should be claims 50-72 as there are only 72 claims present in the application.

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 12/27/06.

The disclosure is objected to because of the following informalities:

On page 27, line 6, the recitation of "lithium" is apparently incorrect. This example is dealing with sodium detection and therefore the instant recitation should apparently be "sodium".

The recitation of "Toluidin" at the end of the legend to Table 6 is apparently incorrect. Apparently the correct recitation should be "Toluidine" as in Table 3 and claims 44, 47, 67 and 71.

Appropriate correction is required.

Claims 35, 43, 49, 56 and 66 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim must refer to the claims in the alternative only. See MPEP \$ 608.01(n).

Application/Control Number: 10/665,883

Art Unit: 1652

Claims 35-36, 43, 45, 47, 49-50, 56-57, 60, 66, 69 and 71 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 35, 43, 49, 56 and 66 are confusing because the claims are dependent upon a non-elected claim.

Claims 36 and 57 are confusing because the arrow does not extend the full length of the term above the arrow. Parts of the term above the arrow might be construed as belonging to the words below it.

Claim 45 is confusing and apparently incorrect in the recitation of "kit of" on line 1, which should apparently be "kit for".

Claims 47 and 71 are confusing in the recitation of "if sodium [lithium] ions are not present". Apparently the specification teaches that the amount of sodium [or lithium] ions present can be determined from the reaction scheme in Tables 3 and 6, and therefore sodium [or lithium] ions are apparently present if product is formed, just a decreasing amount of product is formed with increasing sodium [or lithium].

Claim 50 is confusing in the recitation of "(b)" in line 6. Apparently the correct recitation should be "(a)".

Claim 60 is confusing in the recitation of "a adenosine 3',5'-bisphosphate" in lines 3-4. This instant recitation infers that there is more than one adenosine 3',5'-bishosphate and furthermore the instant recitation should be "an adenosine 3',5'-bisphosphate". Apparently the "a" should be left out as was done in claim 39.

Claim 69 is incorrect in the recitation of "futher", which should apparently be "further".

Application/Control Number: 10/665,883

Art Unit: 1652

•

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 31-72 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

To begin with, the recitation of "Intra-assay", Inter-assay" and "CV%" in Table 4 and Table 7 is not understood. What do these terms refer to?

The instant claims are drawn to "contacting the sample with a sodium-sensitive [or lithium-sensitive] 3'(2'), 5'-bisphosphate nucleotidase". The specification does not teach which 3'(2'), 5'-bisphosphate nucleotidases are sodium-sensitive and which are lithium-sensitive. Without such a teaching one of ordinary skill in the art would be unable to perform the claimed methods. The specification states that "any suitable 3'(2'),5'-bisphosphate nucleotidase can be used" (paragraph 66 and 91) and gives as examples SEQ ID NO:4 and 5 in each paragraph. The specification does not state which 3'(2'),5'-bisphosphate nucleotidases are sensitive to sodium and which ones are sensitive to lithium. Presumably the enzymes of both SEQ ID NO:4 and 5 cannot be sensitive to both or else the assay could not distinguish sodium from lithium.

Apparently the specification teaches the use of a 3'(2'), 5'-bisphosphate nucleotidase that is sensitive to either sodium or lithium to distinguish sodium or lithium ions in the sample. This is done by first making a calibration curve with low and high concentrations of the two ions and then

Art Unit: 1652

- -

seeing where on the calibration curve the unknown sample falls. It is not seen how the chimeric protein containing a leader sequence fits into this.

Is the purpose of this simply to provide a stable enzyme by including a leader sequence?

It is maintained that one of ordinary skill in the art could not practice the claimed invention without undue experimentation.

No art rejection is being made. The examiner could find nothing in the prior art that would anticipate of make obvious the claimed invention.

Lopez-Coronado, et al. (U) and Lurganov, et al. (V) are cited as of interest.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 571-272-0936. The examiner can normally be reached on Monday - Friday from 7:30 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the

Application/Control Number: 10/665,883 Page 6

Art Unit: 1652

Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-

9197 (toll-free).

Charles L. Patterson, Jr.

Primary Examiner Art Unit 1652

Patterson January 27, 2006